MedTrace Logo

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

NCT03009799 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-05-10

No results posted yet for this study

Summary

This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the signs and symptoms of adenoviral conjunctivis

Conditions

  • Adenoviral Conjunctivitis

Interventions

DRUG

Iota-Carrageenan

One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21

DRUG

Carmellose

1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21

Sponsors & Collaborators

  • Iris Pharma

    collaborator INDUSTRY

  • Theradis pharma

    collaborator UNKNOWN

  • NicOx

    lead INDUSTRY

Principal Investigators

  • Brigitte Duquesroix · NicOx

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-08-31
Completion
2017-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03009799 on ClinicalTrials.gov